Market Notice 138/19 – Information regarding the rights issue from DexTech Medical AB

The last day of trading in the company’s shares DEX including the right to receive subscription rights is May 29, 2019. The first day excluding the right to obtain the rights is May 31, 2019.

One (1) share entitles the owner to one (1) subscription right. Eighty-eight (88) subscription rights entitle the owner to subscribe for one (1) new share, at the price of SEK 60,00 (1:88 á SEK 60,00).  

Trading with subscription rights will take place from June 7, 2019 until June 24, 2019 on Spotlight Stock Market.

Trading with the paid subscribed shares will take place from June 7, 2019 until the registration of the issue at Bolagsverket.  

The subscription period lasts from June 7, 2019 to June 26, 2019.

Information about the subscription right:  
Shortname: DEX TR
ISIN-code: SE0012702553
Orderbook-ID: 57H8
CFI: RSSXXR
FISN: DEXTECHMED/SUBS RTS NL PD
First day of trading: June 7, 2019
Last day of trading: June 24, 2019
Market Segment: SPSE
MIC Code: XSAT
Tick table/liquidity band #: A (Other instruments) 

Information about the paid subscribed share:    
Shortname: DEX BTA
ISIN-code: SE0012702561
Orderbook-ID: 57H7
CFI: ESNUFR
FISN: DEXTECHMED/SH
Trading period: June 7, 2019 until the registration of the issue at Bolagsverket.
Market Segment: SPSE
MIC Code: XSAT
Tick table/liquidity band #: A (Other instruments) 

Please be advised that if the rights issue give rise to a conversion factor, all overnight orders in the company’s orderbook will be deleted. If so this will occur after closing on May 29, 2019. 


Stockholm May 27, 2019

Spotlight Stock Market
08-511 68 000
info@spotlightstockmarket.com 

Om oss

DexTech är ett svenskt forskningsföretag specialiserat på urologisk onkologi främst prostatacancer. DexTech utvecklar läkemedelskandidater baserade på en kolhydratmolekyl i kombination med verksamma substanser, bland annat generika. Substanserna har förutsättningar att bli nya läkemedel som tillfredsställer stora behov inom urologisk onkologi. Genom ett nära internationellt/nationellt forsknings- och utvecklingssamarbete med bland annat universitet och sjukhus kan utvecklingen av substanserna genomföras mycket kostnadseffektivt.

Prenumerera

Dokument & länkar